- Home
- DGICA vs CMPX Comparison
DGICA vs CMPX Comparison
Compare DGICA & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGICA
- CMPX
- Stock Information
- Founded
- DGICA 1986
- CMPX 2014
- Country
- DGICA United States
- CMPX United States
- Employees
- DGICA N/A
- CMPX N/A
- Industry
- DGICA Property-Casualty Insurers
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- DGICA Finance
- CMPX Health Care
- Exchange
- DGICA Nasdaq
- CMPX Nasdaq
- Market Cap
- DGICA 705.0M
- CMPX 752.4M
- IPO Year
- DGICA N/A
- CMPX N/A
- Fundamental
- Price
- DGICA $20.00
- CMPX $4.86
- Analyst Decision
- DGICA Hold
- CMPX Strong Buy
- Analyst Count
- DGICA 1
- CMPX 7
- Target Price
- DGICA $18.00
- CMPX $14.43
- AVG Volume (30 Days)
- DGICA 110.3K
- CMPX 2.0M
- Earning Date
- DGICA 10-30-2025
- CMPX 11-05-2025
- Dividend Yield
- DGICA 3.65%
- CMPX N/A
- EPS Growth
- DGICA 219.91
- CMPX N/A
- EPS
- DGICA 2.38
- CMPX N/A
- Revenue
- DGICA $987,826,105.00
- CMPX N/A
- Revenue This Year
- DGICA $2.26
- CMPX N/A
- Revenue Next Year
- DGICA $3.46
- CMPX N/A
- P/E Ratio
- DGICA $8.39
- CMPX N/A
- Revenue Growth
- DGICA 0.89
- CMPX N/A
- 52 Week Low
- DGICA $14.17
- CMPX $1.27
- 52 Week High
- DGICA $21.12
- CMPX $5.05
- Technical
- Relative Strength Index (RSI)
- DGICA 64.30
- CMPX 68.58
- Support Level
- DGICA $19.42
- CMPX $3.50
- Resistance Level
- DGICA $20.00
- CMPX $5.05
- Average True Range (ATR)
- DGICA 0.48
- CMPX 0.32
- MACD
- DGICA 0.12
- CMPX 0.09
- Stochastic Oscillator
- DGICA 97.53
- CMPX 87.42
About DGICA Donegal Group Inc.
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.